Operating loss primarily due to commercialization costs for SB623 and manufacturing and sales approval-related expenses for Akugo; however, ordinary income improved due to foreign exchange gains. The full-year FY2027 outlook is as disclosed, and dividend guidance is undecided. Financial position shows net assets decreased; cash and deposits declined. Going forward, push for proper use of Akugo and accelerate global expansion including the United States.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"SunBio Company Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4592-20260914-01.pdf","jir_short_summary":"Operating loss primarily due to commercialization costs for SB623 and manufacturing and sales approval-related expenses for Akugo; however, ordinary income improved due to foreign exchange gains. The full-year FY2027 outlook is as disclosed, and dividend guidance is undecided. Financial position shows net assets decreased; cash and deposits declined. Going forward, push for proper use of Akugo and accelerate global expansion including the United States.","jir_summary":"### Overview of performance\nDuring this interim period, operating loss arose mainly from SB623 clinical and manufacturing\/sales approval related expenses, while ordinary income declined due to recording foreign exchange gains. Net loss attributable to owners of parent improved year over year. Ongoing efforts to promote appropriate use and to stabilize supply after market launch are expected to contribute to sustainable growth opportunities.\n\n### Financial position and cash flows\nCurrent assets decreased, and cash and deposits declined significantly. Net assets decreased due to lower foreign exchange translation adjustments and recorded interim losses. Cash flows show outflow from operating activities, inflows from investing activities such as redemption of time deposits, and outflows from financing activities including repayment of long-term borrowings.","jir_financial_highlights":"Operating loss: \u25b31,909 million yen (YoY interim period \u25b31,888 million yen)\nOrdinary loss: \u25b31,730 million yen (YoY interim period \u25b32,481 million yen)\nNet loss attributable to owners of parent: \u25b31,791 million yen (YoY interim period \u25b31,997 million yen)\nTotal assets: 13,645 million yen (YoY consolidated end \u22122, -)\nCash and cash equivalents: 12,677 million yen (YoY consolidated end \u22122,138 million yen)","jir_category":"","jir_hashtags":"#SunBio, #FinancialResults, #InterimFinancialResults, #CellTherapy, #SB623","jir_key_figures":"FY2027 interim period Operating loss \u25b31,909 million yen\nFY2027 interim period Ordinary loss \u25b31,730 million yen\nNet loss attributable to owners of parent \u25b31,791 million yen\nCash and cash equivalents 12,677 million yen\nTotal assets 13,645 million yen","jir_meta_title":"SunBio FY2027 Q2 Interim Financial Results Summary | Interim Results and Financial Position","jir_meta_description":"Summary of SunBio's FY2027 Q2 interim consolidated financial results. Includes SB623 development progress, Akugo approval-related costs, currency effects, and plans for global expansion.","jir_og_title":"Summary of SunBio's Interim Financial Results","jir_og_description":"SB623-related costs impacted earnings. Ordinary income improved due to foreign exchange gains. Next, promote Akugo's domestic and international expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-113804","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n